Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

Summary

The purpose of this study is to test the drug erlotinib (erlotinib hydrochloride) in people with malignant peritoneal mesothelioma who have a specific genetic mutation in their cancer. Erlotinib has been approved by the United States Food and Drug Administration (FDA) for other cancers, but erlotinib has not been approved for malignant peritoneal mesothelioma. This research is being done because there is no current standard treatment for malignant peritoneal mesothelioma and the study doctors want to see how erlotinib affects malignant peritoneal mesothelioma.

Timeline

Start

2012-06

Primary completion

2017-02

Completion

2017-02

Drugs

Indications